PGP and metabolic dysfunction-associated steatohepatitis: There were two potential explanations for such difference: one is that the systemic exposure of GS in NASH rats was lower than that in healthy rats after coadministration of SV and GJ, which may result in less potent up-regulation on the expression of P-gp; the other is that the hepatic protein level of P-gp in NASH rats was much higher than that in the healthy rats (Li et al., 2020); therefore, the treatment of GJ was less likely to further up-regulate the P-gp expression.